Athira Pharma raises ~$90M via PIPE and licenses lasofoxifene from Sermonix

LeonaBio, Inc.

PIPE gross proceeds ~$90M; investors include Commodore, TCGX, Perceptive; priced at $6.35/share with warrants.
Sermonix license grants exclusive rights to oral lasofoxifene outside Asia; $34.9M equity issued to Sermonix.
Milestone payments to Sermonix up to $100M; royalties from sub-single to low-single digit percentages.
Ligand agreement imposes separate milestones up to $21M and mid-single to low-double digit royalties.
Commodore and TCGX each get board designee if holding ≥5%; Company to seek resignation of two current directors.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.